Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan Fowler, Sattva S. Neelapu, Larry W. Kwak et al.|The Lancet Oncology|2014Cited by 263
The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with GefitinibLela Buckingham, Philip Bonomi, John S. Coon et al.|Journal of Thoracic Oncology|2007Cited by 40
Chromosome 7 polysomy and biomarker combinations as potential predictors of gefitinib efficacy in non-small cell lung cancer (NSCLC).John S. Coon, Philip Bonomi, Larry E. Morrison et al.|Clinical Cancer Research|2006Cited by 0